Onconova Therapeutics (ONTX) Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer
Go back to Onconova Therapeutics (ONTX) Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer| ONCONOVA THERAPTCS (NYSE: ONTX) | Delayed: 13.69 +1.44 (11.76%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.25 | 52 Week High | $6.71 | |||
| Open | $11.53 | 52 Week Low | $0.32 | |||
| Day High | $13.69 | P/E | N/A | |||
| Day Low | $11.53 | EPS | $-2.36 | |||
| Volume | 4,085 | |||||
